HIV-1 latency reversal agent boosting is not limited by opioid use.

Autor: Lilie TJ; Department of Medicine, Division of Infectious Diseases, Brigham and Women's Hospital, Boston, United States of America., Bouzy J; Department of Medicine, Division of Infectious Diseases, Brigham and Women's Hospital, Boston, United States of America., Asundi A; Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, United States of America., Taylor J; Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, United States of America., Roche S; Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, United States of America., Olson A; Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, United States of America., Coxen K; Department of Medicine, Division of Infectious Diseases, Brigham and Women's Hospital, Boston, United States of America., Corry H; Department of Medicine, Division of Infectious Diseases, Brigham and Women's Hospital, Boston, United States of America., Jordan H; Department of Medicine, Division of Infectious Diseases, Brigham and Women's Hospital, Boston, United States of America., Clayton K; Department of Pathology, University of Massachusetts T.H. Chan School of Medicine, Worchster, United States of America., Lin N; Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, United States of America., Tsibris A; Department of Medicine, Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, United States of America.

Publikováno v: JCI insight [JCI Insight] 2024 Oct 29. Date of Electronic Publication: 2024 Oct 29.